The present laboratory report serves as a comprehensive overview of recent biomedical investigations conducted under the strict ethical guidelines established by institutional review boards operating within Japan Kyoto. As the global healthcare landscape increasingly emphasizes translational medicine and personalized therapeutic interventions, our Medical Researcher team has focused on identifying novel biomarkers associated with early-stage neurodegenerative disorders. The primary objective of this study was to evaluate the efficacy of targeted protein therapies in preclinical models while ensuring strict adherence to the stringent safety protocols mandated by Japanese regulatory bodies. Throughout this investigation, we have maintained a rigorous commitment to data integrity and scientific reproducibility. The findings detailed herein reflect months of meticulous experimentation, sample collection, and statistical analysis performed at our designated facilities in Japan Kyoto. By leveraging advanced genomic sequencing technologies and high-throughput screening assays, our Medical Researcher personnel have successfully identified several promising therapeutic candidates that warrant further clinical evaluation.